By Colin Kellaher
CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.
The Boston clinical-stage company said the Phase 2b study didn't meet statistical significance thresholds for its primary endpoint of change in a measure of the disease or any of its key secondary endpoints.
CervoMed said it is pausing all preparations for a planned Phase 3 study until it completes a full analysis of the Phase 2b study results.
Trading in shares of CervoMed, which closed Monday at $10.25, was halted premarket on Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 10, 2024 07:21 ET (12:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。